Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm

PROGRAM DESCRIPTION Physicians’ Education Resource®, LLC, (PER®) is pleased to present the CME-certified online activity titled "Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm." This innovative ...

PROGRAM DESCRIPTION
Physicians’ Education Resource®, LLC, (PER®) is pleased to present the CME-certified online activity titled "Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm." This innovative activity is an archived version of the live-streamed Medical Crossfire® held on June 25, 2018 at the American Diabetes Association’s 78th Scientific Sessions.

EDUCATIONAL OBJECTIVES
After completing this activity, clinicians should be better able to:Articulate reasons that persons with type 2 diabetes (T2D) fail to achieve target A1C goals and reduce cardiometabolic risk factorsList the potential clinical benefits for achieving glycemic control with newer therapies, especially SGLT2 inhibitors, in persons with T2D and cardiometabolic risk factors at various stages of the diseaseDiscuss results of recent large-scale cardiovascular outcomes trials in persons with T2DDevelop individualized approaches for effectively improving outcomes in persons with T2D and cardiometabolic risk factors

---

Write the first review

Resource tags